(19)
(11) EP 4 770 644 A1

(12)

(43) Date of publication:
08.07.2026 Bulletin 2026/28

(21) Application number: 24858894.9

(22) Date of filing: 30.08.2024
(51) International Patent Classification (IPC): 
A61K 31/437(2006.01)
A61K 31/495(2006.01)
A61K 31/5377(2006.01)
 A61K 31/4745(2006.01)
A61K 31/519(2006.01)
A61P 35/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61P 35/00; A61K 45/06; A61K 31/495; A61K 31/437
 
C-Sets:
  1. A61K 31/495, A61K 2300/00;
  2. A61K 31/437, A61K 2300/00;
(86) International application number:
PCT/IB2024/058436
(87) International publication number:
WO 2025/046519 (06.03.2025 Gazette 2025/10)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 31.08.2023 AU 2023902805

(71) Applicants:
  • Antido Therapeutics International Sàrl
    4051 Basel (CH)
  • Bickerdike, Michael John
    Auckland 1071 (NZ)

(72) Inventor:
  • Bickerdike, Michael John
    Auckland 1071 (NZ)

(74) Representative: Mewburn Ellis LLP 
Aurora Building Counterslip
Bristol BS1 6BX
Bristol BS1 6BX (GB)

   


(54) COMBINATION FOR USE IN THE TREATMENT OF GLIOMA